Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is a rare, gastroenterologic disease characterized by typical clinical, endoscopic and histological features of eosinophilic oesophagitis (i.e. symptomatic oesophageal dysfunction associated with eosinophil-predominant mucose infiltrate) which completely remits upon proton pump inhibitor therapy.
No clinical trials have been registered for proton-pump inhibitor-responsive esophageal eosinophilia.
4 publications have been identified in PubMed for proton-pump inhibitor-responsive esophageal eosinophilia. Research spans Review / Meta-Analysis (50%), Case Report / Case Series (25%), and Epidemiology / Natural History (25%).
Salzano S (2025). [PMID: 41374392](https://pubmed.ncbi.nlm.nih.gov/41374392/). *Diagnostics (Basel, Switzerland)*. [Review / Meta-Analysis]
Canonica GW (2025). [PMID: 39877128](https://pubmed.ncbi.nlm.nih.gov/39877128/). *The journal of allergy and clinical immunology. Global*. [Review / Meta-Analysis]
Rabinowitz SS (2025). [PMID: 40386361](https://pubmed.ncbi.nlm.nih.gov/40386361/). *Translational pediatrics*. [Case Report / Case Series]
Nader LS (2024). [PMID: 38650863](https://pubmed.ncbi.nlm.nih.gov/38650863/). *Frontiers in allergy*. [Epidemiology / Natural History]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center